Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial

  1. Ravassa, S.
  2. López, B.
  3. Ferreira, J.P.
  4. Girerd, N.
  5. Bozec, E.
  6. Pellicori, P.
  7. Mariottoni, B.
  8. Cosmi, F.
  9. Hazebroek, M.
  10. Verdonschot, J.A.J.
  11. Cuthbert, J.
  12. Petutschnigg, J.
  13. Moreno, M.U.
  14. Heymans, S.
  15. Staessen, J.A.
  16. Pieske, B.
  17. Edelmann, F.
  18. Clark, A.L.
  19. Cleland, J.G.F.
  20. Zannad, F.
  21. Díez, J.
  22. González, A.
Revista:
European Journal of Heart Failure

ISSN: 1879-0844,  1388-9842

Ano de publicación: 2022

Volume: 24

Número: 2

Páxinas: 321-331

Tipo: Artigo

DOI: 10.1002/EJHF.2394 GOOGLE SCHOLAR lock_openAcceso aberto editor
Fonte de datos: Scopus